CJC-1295 (NO DAC) + Ipamorelin Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks on, 4 weeks off; some protocols extend to 16 weeks on with proportionally longer breaks
• Frequency: Once daily (before bed, minimum) to three times daily for advanced goals; the nighttime injection is always the anchor
• Common delivery routes: Subcutaneous injection only
• Key timing notes: Both peptides must be injected in a fasted state; eating close to a dose blunts the GH pulse

Who This Protocol Is For

The CJC-1295 (No DAC) + Ipamorelin stack attracts people who want to work with their body's natural growth hormone rhythm rather than override it. Because both peptides amplify pulsatile GH release rather than introducing exogenous growth hormone, the approach tends to feel gradual and clean compared to synthetic GH protocols.

The goals most commonly associated with this stack fall into a few clear categories. Fat loss and body recomposition are consistently the top use cases, particularly because Ipamorelin does not trigger the voracious hunger that older growth hormone releasing peptides like GHRP-6 are known for. People running a caloric deficit can stay on course without fighting appetite surges. Recovery enhancement, sleep quality improvement, connective tissue support, and general anti-aging are the other primary reasons people choose this combination.

Experience level shapes how someone structures the protocol. Someone new to peptides typically starts with a single daily injection before bed, the lowest-frequency approach and the one that maps most cleanly onto the body's natural nighttime GH secretion peak. More experienced users targeting fat loss or performance often move to two or three daily injections, adding a fasted morning dose and sometimes a post-workout dose on training days.

Delivery method for this stack is subcutaneous injection only. There is no oral, nasal, or sublingual form for either peptide. Anyone pursuing this protocol needs to be comfortable with subcutaneous self-injection, or should work with a clinical provider who administers it.

How Is a CJC-1295 (No DAC) + Ipamorelin Cycle Structured?

The typical cycle follows a consistent arc: an active phase of 8 to 16 weeks, followed by an off period of at least 4 weeks before the next cycle begins. The most commonly cited framework is 8 to 12 weeks on with a 4 week break, which works out to roughly three cycles per year. Some people run longer cycles of 12 to 16 weeks, especially when the goal is connective tissue remodeling or gradual body recomposition, and take proportionally longer breaks.

There is no distinct loading phase for this stack. The protocol does not call for an elevated front-load dose before dropping to a lower maintenance level. Instead, it begins at a consistent working dose and stays there for the full active cycle. Think of it less like priming a pump and more like tuning an instrument: you set the frequency, hold it steady, and let the accumulated response build over weeks.

The off period is built into the design. Continuous use leads to declining receptor sensitivity and reduced effectiveness of subsequent cycles, so the break is part of what makes each cycle work. The full reasoning behind cycling on and off is covered in Off-Cycle Considerations.

How Your Dose Is Determined

What moves a CJC-1295 (No DAC) + Ipamorelin dose:

• Your goal: Goals pull the protocol in different directions. Sleep quality, recovery, and general anti-aging typically call for a single nightly injection toward the lower end of the range. Fat loss and body recomposition protocols commonly use two daily injections, a fasted morning dose plus the before-bed anchor. Maximum performance goals sometimes use three daily injections. The dose per injection stays in a consistent range across goal types, but frequency amplifies the total daily GH stimulus.
• Experience level: People new to this stack typically start at a single daily injection and hold there for the first few weeks before deciding whether to add a second or third. More experienced users with established tolerance often begin at two daily injections. The starting point reflects caution, not a fixed ceiling.
• Delivery route: Both peptides are subcutaneous only. Route does not introduce variation here the way it does for peptides available in multiple forms. Rotating injection sites across the cycle is standard practice to avoid localised tissue irritation.
• Individual response: Two people with the same goal and the same frequency can have meaningfully different experiences. IGF-1 lab monitoring during a cycle is one of the clearest ways to understand how an individual is responding, and some people find a lower frequency produces results comparable to what others achieve at three daily injections.

The fasting window around each injection is effectively part of the dose equation. Insulin suppresses GH secretion, so eating close to a dose directly blunts or eliminates the intended GH pulse. This is one practical reason the before-bed injection is consistently prioritized: most people are naturally fasted by bedtime.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type, your preferred injection frequency, and your experience level with this stack and builds your CJC-1295 (No DAC) + Ipamorelin protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take CJC-1295 (No DAC) + Ipamorelin?

Frequency is one of the most variable elements of this protocol, and it is where the protocol most directly reflects goals.

The before-bed injection is the non-negotiable anchor across all frequency levels. The body's single largest natural GH secretion event occurs during deep, slow-wave sleep. Injecting both peptides in a fasted state before bed amplifies that pulse rather than creating a competing signal at an arbitrary time. If the protocol allows for only one injection per day, the nighttime slot is the right one, every time.

Once daily before bed is the standard starting point for people whose primary goals are sleep quality, recovery, and general wellbeing. Twice daily, adding a fasted morning injection, is the more common structure for fat loss and body recomposition. Three times daily, adding a post-workout or afternoon injection in a fasted window, is used by more experienced users who want to maximize the total daily GH stimulus.

Some people follow a five-on, two-off weekly schedule, dosing Monday through Friday and taking the weekend off. The rationale is allowing some receptor recovery each week, potentially extending the productive period of a cycle without a full break. This is a community-derived approach rather than a clinically validated one, and continuous daily dosing through the cycle is equally common.

The consistent timing rule across all approaches: maintain a fasted window of 90 to 120 minutes before each injection and 30 to 60 minutes of continued fasting afterward. Insulin suppresses GH secretion, so eating close to a dose directly undermines the intended effect.

Loading and Maintenance Phases

As covered in the Cycle Structure section, this stack does not use a traditional loading phase. The protocol begins at the working dose for the chosen frequency and holds there through the full active cycle.

What some sources describe as optional titration involves starting at once daily and adding a second or third injection only after assessing individual tolerance over the first two to four weeks. This is a frequency adjustment, not a dose ramp: the amount per injection stays consistent, and only how many times per day changes.

Off-Cycle Considerations

A break from this stack is part of the protocol design, not an optional add-on. Three reasons drive the off period.

The first is receptor sensitivity. The GHRH receptors (the sites in the pituitary that respond to growth-hormone-releasing signals) that CJC-1295 (No DAC) targets can downregulate with continuous stimulation. The ghrelin receptors (sites triggered by the hunger-related signaling molecule ghrelin) that Ipamorelin targets can do the same. When receptor sensitivity declines, the same dose produces a diminished GH pulse. A break allows those receptors to reset, so the next cycle starts from the same baseline of sensitivity as the first.

The second is antibody management. Prolonged peptide exposure can prompt the immune system to produce antibodies against the peptides, gradually reducing their effectiveness. A cycle break interrupts that process before it becomes a meaningful limitation.

The third is natural GH production. The off period gives the pituitary a chance to run its own GH secretion patterns without external amplification, which matters for long-term hormonal balance.

The most consistently cited off duration is 4 weeks, described as a minimum rather than a fixed target. People running longer active cycles of 12 to 16 weeks sometimes take breaks of 6 to 8 weeks. The general principle is that the off period should be proportional to the active phase: the longer the cycle, the more recovery time serves the next one.

What to Expect Week by Week

• Days 1 to 7: Many users commonly report sleep improvements within the first few days, including deeper sleep cycles, more vivid dreams, and waking more rested. Research and user logs suggest some people notice a mild, transient tingling or warmth for about 10 minutes after injection. Muscle soreness from training tends to ease in this first week.
• Weeks 2 to 3: Many users report that recovery continues to improve noticeably. Training sessions feel less draining, and the ability to train hard on consecutive days becomes easier. Subtle changes in body composition begin to appear, though they are often more felt than visible at this stage.
• Weeks 3 to 6: User logs suggest strength gains become more apparent across this stretch. Weights that felt challenging at the start of the cycle feel more manageable. Fat loss begins to show visually, particularly for people running a caloric deficit. The combination of improved recovery and better training quality compounds over this period.
• Weeks 6 to 8: Skin texture and elasticity improvements show up consistently in longer user logs. Joint comfort and connective tissue resilience are commonly reported in this window, particularly for people with pre-existing joint discomfort.
• Beyond 8 weeks: Body recomposition effects become more visible and more stable. Lean mass improvements, reduced waist measurements, and maintained or increased strength are the consistent markers in people who complete full cycles through this point.

These are commonly reported ranges drawn from community protocol data and real-world user logs, not clinical trial outcomes. Individual results vary based on frequency, cycle length, product quality, diet, and training consistency.

For someone running a well-structured fat loss or recomposition cycle, the arc commonly looks like this: sleep and recovery are the obvious early signals, performance and composition both shift gradually through weeks two to six, and the recomposition effects become clearly visible in the final stretch, with lean mass holding steady or increasing while body fat decreases. That gradual, cumulative progression is what a protocol working through the body's own GH axis commonly looks like when it is running well.

Common Protocol Mistakes

Confusing the DAC and No-DAC versions. This is the most consequential mistake in the entire protocol. CJC-1295 with DAC has a half-life of approximately 6 to 8 days and is dosed once or twice per week. CJC-1295 without DAC has a half-life of roughly 30 to 60 minutes and requires daily injections to produce meaningful GH pulses. Using a DAC dosing schedule with the No-DAC compound produces missed GH pulses and little to no meaningful effect. Some vendor labels simply say "CJC-1295" without specifying which variant. If no variant is indicated, assume No-DAC and confirm before proceeding.

Eating too close to an injection. Insulin suppresses GH secretion. A carbohydrate-containing meal or snack within the fasting window blunts or eliminates the GH pulse the peptides are meant to produce. The fasting window is not a suggestion. Many people who report disappointing results are unknowingly invalidating most of their injections by eating too close to the dose.

Skipping the before-bed injection. The nighttime injection is the one that matters most because it aligns with the body's largest natural GH secretion event. Missing daytime injections is less costly. Missing the before-bed dose consistently undermines the core mechanism of the protocol.

Dose calculation errors. Both peptides require reconstitution and careful conversion of the target dose into the correct syringe volume for the specific vial concentration. Misjudging this is common, particularly with insulin syringes where small volumes need to be read precisely. Accurate dose conversion is handled for you in the MyPeptidePal Protocol Creator, which builds the calculation from your specific protocol parameters.

Skipping the off period. Running back-to-back cycles without a break reduces receptor sensitivity over time, producing diminishing returns: the second cycle feels like less than the first, and the gap widens. Honoring the minimum 4 week off period preserves the effectiveness of subsequent cycles.

Sourcing from unverifiable suppliers. Product quality varies significantly. Reports of minimal IGF-1 elevation after a full cycle are often traced to underdosed or counterfeit product rather than non-response. Working with sources that provide third-party testing, manufacturing standards, and verified chain of custody is the practical safeguard.

Neither CJC-1295 (No DAC) nor Ipamorelin is FDA-approved for human use. Both are prohibited under WADA rules, making them off-limits for competitive athletes subject to drug testing.

Frequently Asked Questions

How long is a typical CJC-1295 (No DAC) + Ipamorelin cycle?

Most protocols run 8 to 12 weeks on, followed by a 4 week off period, producing roughly three cycles per year. Some people extend the active phase to 16 weeks for goals like connective tissue remodeling or gradual body recomposition, with a proportionally longer break. The cycle length that fits your goals and schedule is built individually in the MyPeptidePal Protocol Creator.

How often do you take CJC-1295 (No DAC) + Ipamorelin?

The protocol runs once, twice, or three times daily depending on the goal. The before-bed injection is the anchor across all frequency levels because it amplifies the body's natural nighttime GH secretion peak. A fasted morning injection is added for fat loss goals, and a post-workout or afternoon injection is used by some experienced users pursuing maximum effect.

Does CJC-1295 (No DAC) + Ipamorelin need a loading phase?

No. This stack does not use a traditional loading phase. The protocol begins at the working dose for the chosen frequency and stays consistent through the active cycle. Some people start at once daily and add a second injection after a few weeks of assessing tolerance, but that is a gradual frequency increase, not a front-loaded dose ramp.

Do you need to cycle off CJC-1295 (No DAC) + Ipamorelin?

Yes, a break is part of the protocol design. Continuous use leads to declining sensitivity in the receptors both peptides target, reducing their effectiveness over time. A minimum 4 week off period allows receptor sensitivity to reset, limits antibody buildup against the peptides, and gives the pituitary time to run its own GH secretion patterns. Skipping the break typically means diminishing returns on the next cycle.

Why is Ipamorelin paired with CJC-1295 (No DAC) rather than other GHRPs?

The two peptides work through different receptor pathways, CJC-1295 (No DAC) on GHRH receptors and Ipamorelin on ghrelin receptors, and when both signals arrive at the pituitary simultaneously the resulting GH pulse is larger than either compound produces alone. Ipamorelin is preferred over older alternatives in this class because it produces minimal appetite stimulation and does not significantly elevate cortisol, which makes the combination cleaner and better suited to fat-loss and recomposition goals.

What does it mean if IGF-1 does not rise after several weeks on this stack?

Minimal IGF-1 elevation after four to six weeks is most commonly traced to two causes: the fasting window is not being honored around injections, or the product quality is poor. Elevated insulin from eating too close to a dose blunts the GH pulse directly. Underdosed or counterfeit product produces the same outcome regardless of proper timing. If IGF-1 is not moving and the fasting protocol is solid, verifying product quality through a source with third-party testing is the logical next step.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for CJC-1295 (No DAC) + Ipamorelin in one place.